Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization
- 22 June 2021
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (11) , 3196-3203
Abstract
Background and Aim: Size and number are major determinants of tumor burden in hepatocellular carcinoma (HCC). Patients with HCC undergoing transarterial chemoembolization (TACE) have variable outcomes due to heterogeneity of tumor burden. Recently, tumor burden score (TBS) was proposed to evaluate the extent of tumor involvement. However, the prognostic accuracy of TBS has not been well evaluated in HCC. This study aimed to assess its prognostic role in HCC patients undergoing TACE.Methods: A total of 935 treatment‐naïve HCC patients receiving TACE were retrospectively analyzed. Multivariate Cox proportional hazards model was used to determine independent prognostic predictors.Results: Tumor burden score tended to increase with increasing size and number of tumors in study patients. The Cox model showed that serum creatinine ≥ 1.2 mg/dL (hazard ratio [HR]: 1.296, 95% confidence interval [CI]: 1.077–1.559, P = 0.006), serum α‐fetoprotein ≥ 400 ng/dL (HR: 2.245, 95% CI: 1.905–2.645, P < 0.001), vascular invasion (HR: 1.870, 95% CI: 1.520–2.301, P < 0.001), medium TBS (HR: 1.489, 95% CI: 1.206–1.839, P < 0.001) and high TBS (HR: 2.563, 95% CI: 1.823–3.602, P < 0.001), albumin–bilirubin (ALBI) grade 2–3 (HR: 1.521, 95% CI: 1.291–1.792, P < 0.001), and performance status 1 (HR: 1.362, 95% CI: 1.127–1.647, P < 0.001) and status 2 (HR: 1.553, 95% CI: 1.237–1.948, P < 0.001) were associated with increased mortality. Patients with high TBS had poor overall survival in Barcelona Clinic Liver Cancer stage B/C and different ALBI grades.Conclusions: Tumor burden score is a feasible new prognostic surrogate marker of tumor burden in HCC and can well discriminate survival in patients undergoing TACE across different baseline characteristics.Keywords
Funding Information
- Taipei Veterans General Hospital (VN110‐02, V110C‐001)
This publication has 30 references indexed in Scilit:
- Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolizationJournal of Hepatology, 2015
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI GradeJournal of Clinical Oncology, 2015
- Vascular Invasion in Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2014
- Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer systemHepatology, 2012
- Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort studyEuropean Journal of Radiology, 2012
- Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapyBMC Gastroenterology, 2010
- Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolizationLiver International, 2009
- X-TileClinical Cancer Research, 2004
- Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long‐term outcomeAlimentary Pharmacology & Therapeutics, 2004
- Key Concepts in Model Selection: Performance and GeneralizabilityJournal of Mathematical Psychology, 2000